Flag of the European Union EU Clinical Trials Register Help

Clinical trials for TGF-β

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: TGF-β. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-002349-50 Sponsor Protocol Number: M16TGA Start Date*: 2017-09-29
    Sponsor Name:Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL)
    Full Title: Phase I/II study with galunisertib (LY2157299) combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer and an activated TGF-β signature
    Medical condition: colorectal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021639-15 Sponsor Protocol Number: GC1008 Start Date*: 2011-07-07
    Sponsor Name:University Medical Center Groningen
    Full Title: Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging.
    Medical condition: High grade malignant glioma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002419-14 Sponsor Protocol Number: IRST189.04 Start Date*: 2015-09-02
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PRE...
    Medical condition: metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002231-27 Sponsor Protocol Number: LOB-LEV-2005-02 Start Date*: 2006-01-16
    Sponsor Name:Clínica del Dr. Lobatón
    Full Title: Estudio prospectivo, in vivo, aleatorizado, controlado, abierto, de fase IV, en grupos paralelos para medir el efecto de los antihistamínicos (levocetirizina 5 mg/día y ebastina 20 mg/día, vía oral...
    Medical condition: Rinitis alérgica estacional
    Disease: Version SOC Term Classification Code Term Level
    7.1 10039776 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002518-35 Sponsor Protocol Number: 2011-402 Start Date*: 2012-02-22
    Sponsor Name:Karl Emil Kristensen
    Full Title: The effect of aldosterone on the development of chronic allograft nephropathy after kidney transplantation
    Medical condition: Chronic allograft nephropathy in kidney transplants, defined as tubular atrophy and interstitial fibrosis in graft biopsy (Banff criteria)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10063209 Chronic allograft nephropathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005234-36 Sponsor Protocol Number: NR001-03 Start Date*: 2008-11-20
    Sponsor Name:NovaRx Corporation
    Full Title: Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002079-36 Sponsor Protocol Number: 73750 Start Date*: 2020-10-20
    Sponsor Name:Amsterdam University Medical Centers
    Full Title: TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)
    Medical condition: Esophageal squamous cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000334-17 Sponsor Protocol Number: TRACK_001 Start Date*: 2023-03-31
    Sponsor Name:The George Institute of Global Health
    Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial
    Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004052-11 Sponsor Protocol Number: UC-HNG/1909 Start Date*: 2020-07-08
    Sponsor Name:UNICANCER
    Full Title: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma
    Medical condition: Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a di...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041824 Squamous cell carcinoma of esophagus LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041859 Squamous cell carcinoma of the oral cavity stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041860 Squamous cell carcinoma of the oral cavity stage I LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041861 Squamous cell carcinoma of the oral cavity stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041862 Squamous cell carcinoma of the oral cavity stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041863 Squamous cell carcinoma of the oral cavity stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031113 Oropharyngeal squamous cell carcinoma recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031114 Oropharyngeal squamous cell carcinoma stage 0 LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031115 Oropharyngeal squamous cell carcinoma stage I LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021052 Hypopharyngeal squamous cell carcinoma recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021053 Hypopharyngeal squamous cell carcinoma stage 0 LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021055 Hypopharyngeal squamous cell carcinoma stage II LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021054 Hypopharyngeal squamous cell carcinoma stage I LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041854 Squamous cell carcinoma of the hypopharynx stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041853 Squamous cell carcinoma of the hypopharynx stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041855 Squamous cell carcinoma of the hypopharynx stage IV LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023856 Laryngeal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023612-14 Sponsor Protocol Number: N/A Start Date*: 2013-03-08
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic reso...
    Medical condition: Marfan syndrome.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10026829 Marfan's syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005389-51 Sponsor Protocol Number: RB15.210 Start Date*: 2017-10-06
    Sponsor Name:CHRU DE BREST
    Full Title: Safety and Efficacy of tocilizuMAb versus placebo in Polymyalgia rHeumatica with glucocORticoid dEpendence SEMAPHORE
    Medical condition: Polymyalgia rHeumatica
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10036099 Polymyalgia rheumatica PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001280-13 Sponsor Protocol Number: A536-05 Start Date*: 2014-09-03
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolle...
    Medical condition: Myelodysplastic Syndromes (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004519-31 Sponsor Protocol Number: ENTERL08784 Start Date*: 2019-01-31
    Sponsor Name:Sanofi
    Full Title: Randomized, placebo-controlled, clinical trial to evaluate the efficacy of probiotic Bacillus clausii in the treatment of pediatric patients with irritable bowel syndrome
    Medical condition: Irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-002701-94 Sponsor Protocol Number: FUN-PIR-2020-01 Start Date*: 2021-08-13
    Sponsor Name:Fundación para la Gestión de la Investigación Biomédica de Cádiz
    Full Title: Pirfenidone for the reduction of pulmonary inflammatory and fibrogenic activity in patients with silicosis due to artificial stone and progressive massive fibrosis.
    Medical condition: progressive massive fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10040678 Silicosis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10036805 Progressive massive fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001929-40 Sponsor Protocol Number: AZT_DSTB_BB Start Date*: 2017-11-21
    Sponsor Name:University Medical Center Groningen
    Full Title: A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis
    Medical condition: Pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037440 Pulmonary tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020404-29 Sponsor Protocol Number: H9V-MC-GFRF Start Date*: 2011-04-08
    Sponsor Name:Eli Lilly and Company Limited, Indianapolis
    Full Title: A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 D...
    Medical condition: Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004728-36 Sponsor Protocol Number: 747-301 Start Date*: 2012-03-30
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis
    Medical condition: Primary biliary cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022160-13 Sponsor Protocol Number: H9H-MC-JBAI Start Date*: 2011-02-21
    Sponsor Name:Eli Lilly and Company
    Full Title: Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma
    Medical condition: Glioblastoma Multiforme (GBM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003817-80 Sponsor Protocol Number: GFT505B-216-1 Start Date*: 2017-05-22
    Sponsor Name:Genfit SA
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg after 12 Weeks of Treatment in Patients Wit...
    Medical condition: Primary biliary cholangitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004871 10034176 PBC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-005096-27 Sponsor Protocol Number: MBPS205 Start Date*: 2017-06-23
    Sponsor Name:Mereo BioPharma 3 Ltd.
    Full Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusu...
    Medical condition: Osteogenesis imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 19:56:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA